Anti-apoptopic gene SCC-S2 and diagnostic and therapeutic uses thereof
AssigneesGeorgetown University, NeoPharm, Inc.
InventorsUsha Kasid, Deepak Kumar, Prafulla Gokhale, Imran Ahmad
Life of this patent
Estimating the term…
Abstract
A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous leukemia, lung, lymphoblastic leukemia, and colorectal adenocarcinoma cells.
Claims42
As isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
- (a) a polynucleotide encoding amino acids from about 1 to about 188 of the amino acid sequence contained in FIG. 1;
- (b) a polynucleotide encoding amino acids from about 2 to about 188 of the amino acid sequence contained in FIG. 1;
- the polynucleotide complement of the polynucleotide of (a) or (b);
- and
- (c) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).
An isolated nucleic acid molecule comprising about 10 to about 564 contiguous nucleotides from the coding region identified in FIG. 1.
An isolated nucleic acid molecule comprising about 50 to about 564 contiguous nucleotides from the coding region of the nucleic acid sequence in FIG. 1.
An isolated nucleic acid molecule comprising about 100 to about 400 contiguous nucleotides of the coding region of the nucleic acid sequence contained in FIG. 1.
An isolated nucleic acid molecule comprising about 10 to about 564 contiguous nucleotides from the coding region contained in FIG. 1.
An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1;
- and
- (b) amino acids from about 2 to about 188 of the amino acid sequence in FIG. 1.
An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 188 of the amino acid sequence contained in FIG. 1;
- and
- (b) amino acids from about 2 to about 188 of the open amino acid sequence contained in FIG. 1.
An isolated polypeptide wherein, except for at least one conservative amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1;
- and
- (b) amino acids from about 2 to about 188 of the amino acid sequence in FIG. 1.
An isolated polypeptide comprising amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 188 of the amino acid sequence in FIG. 1;
- and
- (b) amino acids from about 2 to 188 of the amino acid sequence in FIG. 1.
An epitope-bearing portion of the polypeptide identified in FIG. 1.
A method of inhibiting apoptosis or proliferation of a cancer cell, comprising inhibiting expression of SCC-S2 in said mammalian cell.
An antisense oligonucleotide that inhibits the expression of SCC-S2 in a mammalian cell and has a phosphodiester backbone or modified base composition.
A method of treating cancer characterized by SCC-S2 overexpression by administration of an antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule that inhibits SCC-S2 expression.
A method of treating cancer characterized by SCC-S2 overexpression comprising administering an antibody that specifically binds to SCC-S2.
A method of treating cancer characterized by SCC-S2 overexpression comprising administration of an antibody that specifically binds to SCC-S2, antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule in combination with radiation, radionucleides, anticancer drugs or other biological agents.
A method of treating cancer characterized by SCC-S2 overexpression comprising administration of antibody that specifically binds SCC-S2, antisense oligonucleotide, ribozyme or small interfering RNA (SI RNA) molecule contained in a liposomal formulation, in combination with radiation, radionucleides, anticancer drugs or other biological agents.
A method of detecting cancer characterized by SCC-S2 overexpression comprising detecting the levels of SCC-S2 expression and correlating said level of expression to the presence or absence of cancer.
A method for inhibiting cancer cell proliferation and/or metastasis in a cancer patient comprising administering an antibody that specifically binds to SCC-S2, small molecule SCC-S2 inhibitor, or a ribozyme or antisense oligonucleotide that inhibits SCC-S2 expression.
A method for identifying small molecule inhibitors of the SCC-S2 protein represented by the polypeptide of FIG. 1, wherein the method comprises the steps of:
- (a) determining a three dimensional structure of the SCC-S2 protein;
- (b) identifying an active site in the structure determined in step (a);
- (c) computationally screening a database of compounds to identify molecules that fit in the active site of the protein and selecting the molecules with the highest calculated binding affinity to the protein;
- and
- (d) testing in vitro the SCC-S2 inhibitory activity of the molecules selected in step (c) and identifying one or more SCC-S2 inhibitors.
A method for designing small molecule inhibitors of the SCC-S2 protein represented by the polypeptide of FIG. 1, wherein the method comprises the steps of:
- (a) determining a three dimensional structure of the SCC-S2 protein;
- (b) identifying an active site in the structure determined in step (a);
- (c) computationally modeling a compound that is complementary to the active site of the SCC-S2 protein;
- and
- (d) testing in vitro the SCC-S2 inhibitory activity of the molecules selected in step (c) and identifying one or more SCC-S2 inhibitors.
Dependencies are inferred from the claim text.